Date set for FDA panel on drug-eluting stents
This article was originally published in Clinica
The US FDA will announce tomorrow that it has scheduled an advisory panel meeting on December 7-8 to discuss recent studies that have shown a small, but significant, increase in the rate of death and heart attack due to blood clots linked to drug-eluting stents (DES).
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.